A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) versus Hydroxyurea in Cytoreductive Therapy Naive Essential Thrombocythemia Participants
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme LLC.
Start Date
September 30, 2024
End Date
September 29, 2029
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme LLC.
Start Date
September 30, 2024
End Date
September 29, 2029